New heart disease risk than the test results

An independent external validation of QRISK - a new score for predicting a person's risk of heart disease - showed that better than the tests and should be recommended for use in the United Kingdom with the National Institute of Health and Clinical Excellence (NICE).

The University of Nottingham and the main providers of health care issued by the non-profit QResearch partnership, development of the formula has been very successful in research in the British Medical Journal.

Researchers from Oxford University have recommended the widespread use in the United Kingdom where the most commonly used Framingham equation.

Professor Julia Hippisley-Cox of the University of Nottingham's Division of Primary Care, said: "We expect further strong support for the value of QRISK in assessing the risk of heart disease in the UK population. We believe that this formula has the potential for thousands of lives, and more doctors to accurately predict the risk of developing cardiovascular disease - the biggest killer of the nation. It is the arm of the doctors all the information they need to decide how best to target the patient through preventive measures such as advice lifestyle and cholesterol-lowering therapies. "

Soon, each patient record contains a calculated risk heart automatically result allows doctors to identify and risks are greatest.

NICE currently recommends that doctors with a modified version of the long-established to determine the results of Framingham, statins are the treatment to reduce the risk of heart disease in the next 10 years.

However, in 2007, the BMJ publishes research shows that the new QRISK ® resulted in a more accurate measure of the United Kingdom, like many adults are at risk of developing cardiovascular disease and adults most likely to receive treatment, compared to the Framingham model. Now, two independent experts, the performance of these two values for predicting 10-year risk of cardiovascular disease in Britain more than a million patients.

It follows the progress of 1.07 million patients in 274 practices in England and Wales to 12 years after the first diagnosis of cardiovascular disease. All participants were aged 35 to 74 at baseline.

The 56% of physicians in the United Kingdom, clinical records EMIS systems may already be on QRISK2 formula that is integrated into their systems.

EMIS manager Sean Riddell, said: "We are delighted to confirm that all EMIS GPS QRISK enjoy now, and we want to thank all those doctors, who are an anonymous patient data to support development this important clinical tool. "

Other suppliers of clinical systems are able to access QRISK by a software development kit has been developed for safety and proper use of the formula. QRISK The software is also for scientific research and teaching and personal use.

QRISK See www.qrisk.org

The research was QRISK with QResearch primary health care database limited at the University of Nottingham, in cooperation with the University of Edinburgh, Bristol PCT and St Mary's School of Medicine and Dentistry, London.